Trial results
$ZLAB — Zocilurtatug pelitecan (zoci; formerly ZL-1310)
Zai Lab Ltd (ZLAB) Zocilurtatug pelitecan (zoci; formerly ZL-1310): trial results in Second-line plus extrapulmonary neuroendocrine carcinomas (2L+ epNECs), 2027.
The catalyst
"Based on feedback from the U.S. Food and Drug Administration (FDA), Zai Lab will pursue a potential accelerated approval pathway based on this single-arm expansion study with topline data expected in the first half of 2027."
— Zai Lab, 8-K filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
ZLAB-ZOCILURTATUG-2026- Company
- Zai Lab Ltd
- Kind
- Trial results
- Indication
- Second-line plus extrapulmonary neuroendocrine carcinomas (2L+ epNECs)
- Window
- 2027-01-01 – 2027-06-30
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.